Back to Journals » Therapeutics and Clinical Risk Management » Volume 4 » Issue 1

Therapeutic options for chronic myeloid leukemia: focus on imatinib (Glivec®, Gleevec™)

Authors Martin Henkes, Heiko van der Kuip, Walter E Aulitzky

Published 8 February 2008 Volume 2008:4(1) Pages 163—187

DOI https://doi.org/10.2147/TCRM.S1527

1Martin Henkes, 2Heiko van der Kuip, 1Walter E Aulitzky

12nd Department of Internal Medicine, Oncology and Hematology, Robert Bosch Hospital, Auerbachstr. 110, Stuttgart, Germany; 2Dr Margarete Fischer-Bosch Institute of Clinical Pharmacology, Auerbachstr. 112, Stuttgart, and University of Tuebingen, Germany

Abstract: Treatment options for chronic myeloid leukemia (CML) have changed dramatically during the last decades. Interferon-α treatment and stem cell transplantation (SCT) clearly improved survival over conventional chemotherapy and offered the possibility of complete and durable responses. With the advent of the small molecule inhibitor imatinib mesylate (Glivec®, GleevecTM) targeting the causative Bcr-Abl oncoprotein, the era of molecular cancer therapy began with remarkable success especially in chronic phase patients. Today, imatinib is the first-line treatment for CML. However, imatinib does not appear to be capable to eliminate all leukemia cells in the patients and pre-existing as well as acquired resistance to the drug has been increasingly recognized. To overcome these problems, several strategies involving dose escalation, combinations with other agents, and novel Bcr-Abl inhibitors have been developed.

Keywords: CML therapy, imatinib, SCT, novel kinase inhibitors

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 

 

Readers of this article also read:

A peptide-mediated targeting gene delivery system for malignant glioma cells

Wang C, Ning L, Wang H, Lu Z, Li X, Fan X, Wang X, Liu Y

International Journal of Nanomedicine 2013, 8:3631-3640

Published Date: 24 September 2013

Socioeconomic status in HCV infected patients – risk and prognosis

Omland LH, Osler M, Jepsen P, Krarup H, Weis N, Christensen PB, Roed C, Sørensen HT, Obel N

Clinical Epidemiology 2013, 5:163-172

Published Date: 31 May 2013

A characteristic optic disc appearance associated with myopia in subjects with Graves' ophthalmopathy and in subjects with primary open-angle glaucoma

Yamazaki S, Inoue R, Tsuboi T, Kozaki A, Inoue T, Inoue T, Inoue Y

Clinical Ophthalmology 2013, 7:47-53

Published Date: 7 January 2013

Unexplained postoperative retinal hemorrhage after 23-gauge sutureless vitrectomy

Ohno H, Inoue K

Clinical Ophthalmology 2011, 5:1027-1029

Published Date: 26 July 2011

Comparison of skin microvascular reactivity with hemostatic markers of endothelial dysfunction and damage in type 2 diabetes

Sandra Beer, François Feihl, Juan Ruiz, Irène Juhan-Vague, Marie-Françoise Aillaud, et al

Vascular Health and Risk Management 2008, 4:1449-1458

Published Date: 5 December 2008

Homocysteine and carotid intima-media thickness in ischemic stroke patients are not correlated

George Ntaios, Christos Savopoulos, Apostolos Hatzitolios, Ippoliti Ekonomou, Evangelos Destanis, et al

Neuropsychiatric Disease and Treatment 2008, 4:477-479

Published Date: 11 April 2008